These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16604138)

  • 21. [Muscle weakness and intolerance to exercise in mitochondrial myopathies].
    Peluchetti D; Antozzi C; Roi GS; Rimoldi M; Cornelio F
    Acta Neurol (Napoli); 1989 Oct; 11(5):335-45. PubMed ID: 2603780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic Myopathies.
    Tarnopolsky MA
    Continuum (Minneap Minn); 2022 Dec; 28(6):1752-1777. PubMed ID: 36537979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise efficiency impairment in metabolic myopathies.
    Noury JB; Zagnoli F; Petit F; Marcorelles P; Rannou F
    Sci Rep; 2020 May; 10(1):8765. PubMed ID: 32472082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic myopathies: functional evaluation by different exercise testing approaches.
    Volpi L; Ricci G; Orsucci D; Alessi R; Bertolucci F; Piazza S; Simoncini C; Mancuso M; Siciliano G
    Musculoskelet Surg; 2011 Aug; 95(2):59-67. PubMed ID: 21373907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New approaches for the treatment of metabolic myopathies].
    Laforêt P; Nicolino M; Eymard B
    Rev Neurol (Paris); 2007 Oct; 163(10):930-5. PubMed ID: 18033029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal blood lactate accumulation after exercise in patients with multiple mitochondrial DNA deletions and minor muscular symptoms.
    Lindholm H; Löfberg M; Somer H; Näveri H; Sovijärvi A
    Clin Physiol Funct Imaging; 2004 Mar; 24(2):109-15. PubMed ID: 15056184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic myopathies.
    Martin A; Haller RG; Barohn R
    Curr Opin Rheumatol; 1994 Nov; 6(6):552-8. PubMed ID: 7865373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and metabolic responses to exercise in a patient with McArdle's syndrome.
    Porte D; Crawford DW; Jennings DB; Aber C; McIlroy MB
    N Engl J Med; 1966 Aug; 275(8):406-12. PubMed ID: 5222164
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolic neuropathies and myopathies.
    D'Amico A; Bertini E
    Handb Clin Neurol; 2013; 113():1437-55. PubMed ID: 23622366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. McArdle's disease: a clinical review and case report.
    Keel BR; Brit M
    Tenn Med; 2013; 106(10):33, 37. PubMed ID: 24282836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of lipid peroxidation in McArdle's disease: applications for treatment of other myopathies.
    Russo PJ; Phillips JW; Seidler NW
    Med Hypotheses; 1992 Oct; 39(2):147-51. PubMed ID: 1461177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiopulmonary Exercise Testing and Metabolic Myopathies.
    Riley MS; Nicholls DP; Cooper CB
    Ann Am Thorac Soc; 2017 Jul; 14(Supplement_1):S129-S139. PubMed ID: 28590155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double trouble (McArdle's disease and myasthenia gravis): how can exercise help?
    Lucia A; Maté-Muñoz JL; Pérez M; Foster C; Gutiérrez-Rivas E; Arenas J
    Muscle Nerve; 2007 Jan; 35(1):125-8. PubMed ID: 16967472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycogen storage disease type V (Mc Ardle's disease): a report on three cases.
    Krishnamoorthy N; Santosh V; Yasha TC; Mahadevan A; Shankar SK; Jethwani D; Taly AB; Bhanu K; Gayathri N
    Neurol India; 2011; 59(6):884-6. PubMed ID: 22234204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninflammatory myopathies.
    Baer AN; Wortmann RL
    Rheum Dis Clin North Am; 2013 May; 39(2):457-79. PubMed ID: 23597974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic myopathies.
    Wortmann RL
    Curr Opin Rheumatol; 1991 Dec; 3(6):925-33. PubMed ID: 1772746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fat metabolism during exercise in patients with McArdle disease.
    Ørngreen MC; Jeppesen TD; Andersen ST; Taivassalo T; Hauerslev S; Preisler N; Haller RG; van Hall G; Vissing J
    Neurology; 2009 Feb; 72(8):718-24. PubMed ID: 19237700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic risk factors associated with lipid-lowering drug-induced myopathies.
    Vladutiu GD; Simmons Z; Isackson PJ; Tarnopolsky M; Peltier WL; Barboi AC; Sripathi N; Wortmann RL; Phillips PS
    Muscle Nerve; 2006 Aug; 34(2):153-62. PubMed ID: 16671104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fat metabolism during exercise: a review. Part I: fatty acid mobilization and muscle metabolism.
    Jeukendrup AE; Saris WH; Wagenmakers AJ
    Int J Sports Med; 1998 May; 19(4):231-44. PubMed ID: 9657362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.